Plexus Corporation (PLXS) Q3 2024 Earnings Call Transcript Summary
Plexus Corporation (PLXS) Q3 2024 Earnings Call Transcript Summary
Free cash flow reached a record high of $194 million for the quarter, pushing annual free cash flow to a historical best of $341 million.The following is a summary of the Plexus Corporation (PLXS) Q3 2024 Earnings Call Transcript:
以下是 Plexus 公司（PLXS）2024年第三季度業績會議議錄摘要：
Financial Performance:
金融業績：
Plexus Corporation announced Q3 revenue of $1.05 billion, surpassing guidance.
Achieved non-GAAP operating margin of 6.2%, exceeding the expected range of 5.6% to 6.0%.
Free cash flow reached a record high of $194 million for the quarter, pushing annual free cash flow to a historical best of $341 million.
Non-GAAP EPS was $1.85, also above the forecasted range.
Plexus 公司宣佈第三季度營業收入爲10.5億美元，超過預期指導。
實現非通用會計準則營業利潤率達到6.2%，超出預期範圍5.6%至6.0%。
季度自由現金流達到創紀錄的19400萬美元，推動年度自由現金流達到歷史最高的34100萬美元。
非通用會計準則每股收益爲1.85美元，也高於預測範圍。
Business Progress:
業務進展：
Won 26 manufacturing programs in the quarter, intending annual revenue ramp-up of $230 million.
Total program wins for fiscal 2024 exceeded $1 billion, with $568 million in the healthcare life sciences sector alone.
Committed to environmental and social initiatives, including a substantial reduction in waste and greenhouse gas emissions, and significant community engagements via the Plexus Community foundation.
季度內贏得了26個製造業項目，計劃年度營收增長至23000萬元。
2024財年總項目獲勝金額超過10億美元，其中僅在醫療生命科學領域就達到了56800萬美元。
致力於環保和社會倡議，包括大幅減少廢物和溫室氣體排放，以及通過普雷克薩斯社區基金會的重大社區參與。
Opportunities:
機會：
Anticipated revenue growth in fiscal 2025 from aerospace and defense sector, driven by new program ramps and market share gains.
Expect moderate growth in healthcare, life sciences, and industrial sectors, fueled by demand recovery and new program wins.
預計2025財年航空航天與國防板塊的營業收入增長，受新項目上升和市場份額增加推動。
預計醫療、生命科學和工業領域將出現適度增長，受需求復甦和新項目獲勝推動。
Risks:
風險：
Projected flat to single-digit decline in Q1 revenue for aerospace and defense reflecting earlier project pooling and cautious market conditions.
Continued inventory corrections in healthcare life sciences sector could dampen the expected growth rates.
預計航空航天與國防業務的Q1營業收入將出現單數位衰減，反映早期項目彙集和謹慎的市場條件。
醫療生命科學領域繼續進行庫存調整可能會降低預期增長率。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
